



JBC Monthly Newsletter

March 2021

JBC Updates

- JBC Cycle 2:** The JBC P30 renewal application was evaluated by the study section at NIAMS on March 1. The reviewers awarded us a **PERFECT SCORE of 10**. We are very grateful for this positive assessment of JBC Cycle 1 and of our plans for JBC Cycle 2.
 - THANK YOU** to all JBC members for your contributions to the JBC so far, including for your help with letters and other information for our 800+ page renewal application.
 - The JBC leadership will be meeting soon to assess our financial status. We had budgeted conservatively in case of an adverse review outcome, but we hope that this positive outcome will allow us to fund another round of **JBC MICROGRANTS** this year. Stay tuned!
- Next JBC Synergy Meeting** will be on March 26th, 12:30-1:30 p.m. Eastern Time via Zoom.

Talk 1: Dr. Kiki Cunningham (BWH), “Immune Checkpoint Inhibitor Treatment in Cancer: Immunomodulator Use and Evaluation by Rheumatology”

Talk 2: Dr. Allen Steere (MGH), “Cell-mediated cytotoxicity in Lyme arthritis”
- Next JBC Aims Review Committee** will be on April 5th, 12-1 p.m. Eastern Time via Zoom. If you are not on the ARC email list and wish to be, please email peter.nigrovic@childrens.harvard.edu.

JBC Member News

JBC MEMBER PUBLICATIONS

Sparks JA. Multimorbidity accrual after incident rheumatoid arthritis: A wolf at the door. J Rheumatol. 2021 (In Press).

Robinette ML, Rao DA, Monach PA. The Immunopathology of Giant Cell Arteritis Across Disease Spectra. Front. Immunol., 25 February 2021 | <https://doi.org/10.3389/fimmu.2021.623716>

Fiechter RH, de Jong HMY, van Mens LJJ, Fluri IA, **Tas SW**, Baeten DLP, Yeremenko NG, van de Sande MGH. IL-12p40/IL-23p40 blockade with ustekinumab decreases the synovial inflammatory infiltrate through modulation of multiple signaling pathways including MAPK-ERK and Wnt Front. Immunol. 2021. doi: 10.3389/fimmu.2021.611656.

The JBC Team:

Peter Nigrovic, M.D.
Director (BCH & BWH)

Human Biosamples Core:

- **Elizabeth Karlson, M.D.**
Director
- **Jeffrey Sparks, M.D., M.M.Sc.**
Associate Director BWH
- **Lauren Henderson, M.D., M.M.Sc.**
Associate Director BCH

Cellular Systems Core:

- **Jim Lederer, Ph.D.**
Director
- **Peter Nigrovic, M.D.**
Associate Director
- **Kevin Wei, M.D., Ph.D.**
Associate Director

Alunno A, Najm A, Machado PM, Bertheussen H, Burmester GR, Carubbi F, De Marco G, Giacomelli R, Hermine O, Isaacs JD, Koné-Paut I, Magro-Checa C, McInnes I, Meroni PL, Quartuccio L, Ramanan AV, Ramos-Casals M, Rodríguez Carrio J, Schulze-Koops H, Stamm TA, **Tas SW**, Terrier B, McGonagle DG, Mariette X. EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. *Ann Rheum Dis*. 2021 Feb 5:annrheumdis-2020-219724. doi: 10.1136/annrheumdis-2020-219724. Epub ahead of print. PMID: 33547062; PMCID: PMC7871226.

Baglaenko Y, Macfarlane D, Marson A, **Nigrovic PA**, **Raychaudhuri S**. Genome editing to define the function of autoimmune loci in rheumatic disease. *Nature Rev Rheum*. 2021. In press.

OPEN POSITIONS

The **Nigrovic lab** (Brigham and Women's Hospital/Boston Children's Hospital) has a postdoctoral position open in the area of neutrophil biology.

The **Shelef lab** (University of Wisconsin - Madison) has a postdoctoral position open in the area of autoantibodies.

The **Wei lab** (Brigham and Women's Hospital) has a postdoctoral position open for project- Spatial transcriptomics and stromal cell biology.